NASDAQ:STOK

Stoke Therapeutics Stock Forecast, Price & News

$66.57

+1.25 (+1.91 %)

(As of 01/15/2021 08:00 PM ET)

Add

Compare

Today's Range

$63.35

Now: $66.57▼

$68.08

50-Day Range

$46.02

MA: $56.41▼

$65.32

52-Week Range

$15.82

Now: $66.57▼

$68.29

Volume6,876 shs

Average Volume145,650 shs

Market Capitalization$2.23 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.23

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Overall MarketRank^™

1.40 out of 5 stars

2.4 Analyst's Opinion

Consensus Rating
Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $62.17, Stoke Therapeutics has a forecasted downside of 6.6% from its current price of $66.57.
Amount of Analyst Coverage
Stoke Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.9 Community Rank

Outperform Votes
Stoke Therapeutics has received 57 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Stoke Therapeutics has received 40 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Stoke Therapeutics has received 58.76% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Stoke Therapeutics and other stocks. Vote “Outperform” if you believe STOK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STOK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Stoke Therapeutics does not currently pay a dividend.
Dividend Growth
Stoke Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stoke Therapeutics insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $14,625,000.00 in company stock and sold $15,077,384.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
54.60% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($1.60) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stoke Therapeutics is -36.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stoke Therapeutics is -36.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Stoke Therapeutics has a P/B Ratio of 9.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:STOK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.stoketherapeutics.com

Phone781-430-8200

Employees56

Debt

Debt-to-Equity RatioN/A

Current Ratio35.41

Quick Ratio35.41

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.86 per share

Price / Book9.70

Profitability

EPS (Most Recent Fiscal Year)($1.80)

Net Income$-32,330,000.00

Net MarginsN/A

Return on Equity-19.53%

Return on Assets-19.03%

Miscellaneous

Outstanding Shares33,470,000

Market Cap$2.23 billion

Next Earnings Date3/22/2021 (Estimated)

OptionableNot Optionable

$66.57

+1.25 (+1.91 %)

(As of 01/15/2021 08:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive STOK News and Ratings via Email

Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

How has Stoke Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STOK shares have increased by 237.4% and is now trading at $66.57.
View which stocks have been most impacted by COVID-19.

Is Stoke Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Stoke Therapeutics stock.
View analyst ratings for Stoke Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Stoke Therapeutics?

Wall Street analysts have given Stoke Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Stoke Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 22nd 2021.
View our earnings forecast for Stoke Therapeutics.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings results on Thursday, November, 12th. The company reported ($0.41) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.41).
View Stoke Therapeutics' earnings history.

What price target have analysts set for STOK?

8 brokers have issued 1 year price objectives for Stoke Therapeutics' stock. Their forecasts range from $49.00 to $72.00. On average, they expect Stoke Therapeutics' stock price to reach $62.17 in the next twelve months. This suggests that the stock has a possible downside of 6.6%.
View analysts' price targets for Stoke Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Stoke Therapeutics' key competitors?

Some companies that are related to Stoke Therapeutics include Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Allakos (ALLK), Galapagos (GLPG), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Schrödinger (SDGR), Amicus Therapeutics (FOLD) and Perrigo (PRGO).
View all of STOK's competitors.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology Group (MRVL) and Invitae (NVTA).

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:

Dr. Edward M. Kaye, CEO & Director (Age 71, Pay $668.37k)
Dr. Adrian R. Krainer Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board (Age 61, Pay $119.5k)
Mr. Stephen J. Tulipano CPA, CPA, MBA, Chief Financial Officer (Age 61, Pay $514.47k)
Ms. Isabel Aznarez, Co-Founder, VP & Head of Biology (Age 48)
Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 53)
Ms. Joan Wood, Head of HR
Dr. Gene Liau, Exec. VP, Head of Research & Preclinical Devel. (Age 65)
Dr. Barry S. Ticho FACC, M.D., Ph.D., Chief Medical Officer (Age 60)
Ms. Shamim Ruff, Sr. VP of Regulatory Affairs & Quality (Age 60)
Ms. Nancy M. Wyant, VP & Head of Clinical Operations (Age 48)

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $66.57.

How big of a company is Stoke Therapeutics?

Stoke Therapeutics has a market capitalization of $2.23 billion. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 56 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here